Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

South Dakota Could Provide Model For Medicare Reform
The Sioux Falls Argus Leader reports: "It might be only a footnote in health care reform this year, or perhaps a consolation prize. Either way, South Dakota ranks among the cheapest states in the nation for doing business through Medicare. The state is No. 47 with expenses averaging $6,253 for each person who uses the federal benefit to pay for health care. The U.S. average is $8,304. Officials attributed South Dakota"s results to local efficiencies and preventive health, and hope the good score might earn the state some benefit in proposed reforms. So far it hasn"t worked out that way, with Medicare cuts at this point appearing to apply evenly to all states. But researcher Elliott Fisher of the Dartmouth Institute for Health Policy and Clinical Practice, says the gap should be a tool in the debate as the government looks for ways to pay for reform." Don't forget to buy zoloft online no prescription.

UCLA Study Discovers Enzyme That Controls 'Bad' Cholesterol
BACKGROUND: Low-density lipoprotein (LDL) is the so-called "bad cholesterol" often linked to medical problems like heart disease and clogged arteries. Cells in the liver produce a specific receptor that sticks to LDL and removes it from the blood, lowering cholesterol levels. Statin drugs also reduce LDL cholesterol levels by boosting cells" production of the receptor.

generic viagra online


News of the day
Biogen Idec Receives Fast Track Designation From FDA For PEGylated Interferon Beta-1a For Relapsing Multiple Sclerosis
Biogen Idec (NASDAQ: BIIB) announced the U.S. Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS). Biogen Idec is currently enrolling patients in a global Phase III study evaluating the efficacy and safety of either bi-weekly or once-monthly injections of PEGylated interferon beta-1a in this patient population.
Public Health

Can-Fite-Completed Patient Enrollment For The Phase II Trial In Psoriasis With CF101

Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, has achieved yet another goal by completion of patients" enrollment in its phase II Psoriasis trial. Approximately 70 patients were enrolled to this study, randomized into 4 groups treated with 1, 2 and 4 mg of CF101 and placebo. Patients are taking the drug for 12 weeks plus 2 weeks of follow-up. The trial is being conducted in 10 sites in Israel and Europe. The company estimates to release study data on Q3 2009. A point to note it that similarly to the patients in the Dry Eye study, which was recently successfully concluded, the patients in the current study were also treated with CF101 as a stand alone. Psoriasis is a skin condition that affects 2% to 3% of the general population. The disease is manifested by scaly plaques on the skin and in the severe form has a major effect on the physical and emotional well-being of the patients. General anti-inflammatory agents such as topical corticosteroids, Methotrexate or phototherapy are only partially effective and are limited by safety issues. Recently, novel biologics targeting the underlying immuno-pathogenesis of the disease have been introduced, such as Enbrel, which blocks the activity of the inflammatory cytokine tumor necrosis factor-í± (TNF-í±). Still, a significant need remains for novel drugs for patients who do not respond to existing therapies or for whom these therapies are unsuitable. The market share for Psoriasis is estimated at US$ 3.5 billion annually. The oral administration of Can-Fite"s CF101, the drug"s mechanism of action (suppression of the inflammatory mediator TNF-í±) and its excellent safety profile (tested on more than 600 subjects in other trials), support its use for the treatment of psoriasis. Prof. Pnina Fishman, CEO of Can-Fite, said today that, "We are very happy with the progress in our clinical development program and looking forward to analyze the data of this study in which CF101 was given as a monotherapy. It is our first trial in the dermatology field and the immuno-modulatory activities of CF101 render it a possible attractive drug candidate for these clinical conditions." Can-Fite Biopharma LTD


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009